Covered recipient · General Payments record
JORGE R ORELLANA
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,286.67
- Reported across 58 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $454.25 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $277.55 | 10 |
| PFIZER INC. | $57.71 | 2 |
| Novo Nordisk AS | $49.19 | 2 |
| Acerta Pharma LLC | $26.22 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $23.33 | 1 |
| Xeris Pharmaceuticals, Inc. | $20.25 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $26.22 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104317140 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $23.33 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086250462 | CMS |
| Lilly USA, LLC | $33.91 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135089289 | CMS |
| Lilly USA, LLC | $28.21 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135079094 | CMS |
| Lilly USA, LLC | $26.07 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135082922 | CMS |
| Lilly USA, LLC | $30.12 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135079088 | CMS |
| Lilly USA, LLC | $31.63 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135096752 | CMS |
| Lilly USA, LLC | $5.31 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135079090 | CMS |
| Lilly USA, LLC | $29.23 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135089287 | CMS |
| Lilly USA, LLC | $31.64 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135082924 | CMS |
| Lilly USA, LLC | $27.81 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135079092 | CMS |
| Lilly USA, LLC | $33.62 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135073723 | CMS |
| Novo Nordisk Inc | $24.53 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097735265 | CMS |
| Novo Nordisk Inc | $24.66 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097272756 | CMS |
| PFIZER INC. | $28.91 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130891942 | CMS |
| PFIZER INC. | $28.80 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130915487 | CMS |
| Xeris Pharmaceuticals, Inc. | $20.25 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144599976 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.